Despite the availability of many treatment options for moderate-to-severe plaque psoriasis, there is still a need for additional therapies. Hear from Ryan Moslin, Principal Scientist, BMS, who has moderate-to-severe plaque psoriasis and Tom Scharnitz, M.D., the Senior Director and US Medical Lead for Dermatology, as they provide the science and research behind an oral treatment for moderate-to-severe plaque psoriasis.